Angiodynamics Inc

AngioDynamics, Inc.

Company Overview
AngioDynamics, Inc. (NASDAQ: ANGO) is a public medical technology company founded in 1988. Headquartered in Latham, New York, the company designs, manufactures, and sells devices for minimally invasive medical procedures. For the twelve months ending in February 2026, the company reported revenue of $314 million. It employs over 1,000 people worldwide.

Products and Operations
AngioDynamics operates as a medical device manufacturer, focused on technologies for vascular access, peripheral vascular disease, and oncology. The company's portfolio is divided into two segments: Med Tech and Med Device. Key product lines include the Auryon Atherectomy System for treating peripheral artery disease, the AngioVac and AlphaVac systems for removing thrombi and emboli, and the NanoKnife system for ablating soft tissue in oncology applications. The company also produces a range of catheters, ports, and other devices used in interventional radiology and surgery.

Patent Litigation Posture
Based on the available data, AngioDynamics is an operating company that actively enforces its intellectual property. The company's litigation history shows one case as a plaintiff and none as a defendant. This posture is consistent with a technology-focused manufacturing company protecting its innovations rather than a non-practicing entity (NPE) that primarily licenses acquired patents. The single tracked case was filed in the District of Delaware, a common venue for corporate and patent litigation.

Notable Cases and Context
The company's sole tracked patent case is Angiodynamics Inc v. Endovascular Engineering Inc, filed on April 23, 2026, in the Delaware District Court. In the lawsuit, AngioDynamics alleges that Endovascular Engineering's Hēlo Thrombectomy System infringes on patents related to its proprietary self-expanding funnel technology, which is designed to improve the removal of blood clots. AngioDynamics is seeking damages and equitable relief to prevent further infringement.